Paper6901593
Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance.
Mandell GL and 1 other. Antimicrob Agents Chemother, 1980. Cited by 63 papers, by iCite.
Cite this record
ConductScience Library. Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance. Papers, record 6901593. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/6901593
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Treatment of experimental staphylococcal infections: effect of rifampin alone and in combination on development of rifampin resistance.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Rifampin | Major topic |
| Staphylococcal Infections | Major topic |
| Acute Disease | |
| Animals | |
| Drug Synergism | |
| Drug Therapy, Combination | |
| Male | |
| Methicillin | |
| Mice | |
| Microbial Sensitivity Tests | |
| Penicillin Resistance | |
| Penicillins | |
| Trimethoprim |
Source PubMed
References6
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 5776003 | Bacteriologic studies of rifampin, a new semisynthetic antibiotic. | J Infect Dis | 1969 | https://conductscience.org/library/papers/5776003 | PubMed |
| 2 | 5023643 | Killing of intraleukocytic Staphylococcus aureus by rifampin: in-vitro and in-vivo studies. | J Infect Dis | 1972 | https://conductscience.org/library/papers/5023643 | PubMed |
| 3 | 4718959 | Interaction of intraleukocytic bacteria and antibiotics. | J Clin Invest | 1973 | https://conductscience.org/library/papers/4718959 | PubMed |
| 4 | 4790559 | Treatment of experimental staphylococcal infection with rifampin. | Antimicrob Agents Chemother | 1972 | https://conductscience.org/library/papers/4790559 | PubMed |
| 5 | 1117067 | Catalase, superoxide dismutase, and virulence of Staphylococcus aureus. In vitro and in vivo studies with emphasis on staphylococcal--leukocyte interaction. | J Clin Invest | 1975 | https://conductscience.org/library/papers/1117067 | PubMed |
| 6 | 666300 | In vitro activity of rifampin alone and in combination with nafcillin and Vancomycin against pathogenic strains of Staphylococcus aureus. | Antimicrob Agents Chemother | 1978 | https://conductscience.org/library/papers/666300 | PubMed |
Cited by22
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 63 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 40392929 | Sulfamethoxazole-trimethoprim plus rifampicin combination therapy for methicillin-resistant Staphylococcus aureus infection: An in vitro study. | PLoS One | 2025 | https://conductscience.org/library/papers/40392929 | PubMed |
| 31106377 | Non-lytic antibiotic treatment in community-acquired pneumococcal pneumonia does not attenuate inflammation: the PRISTINE trial. | J Antimicrob Chemother | 2019 | https://conductscience.org/library/papers/31106377 | PubMed |
| 28245229 | Combinatory antibiotic therapy increases rate of bacterial kill but not final outcome in a novel mouse model of Staphylococcus aureus spinal implant infection. | PLoS One | 2017 | https://conductscience.org/library/papers/28245229 | PubMed |
| 24514089 | Combination prophylactic therapy with rifampin increases efficacy against an experimental Staphylococcus epidermidis subcutaneous implant-related infection. | Antimicrob Agents Chemother | 2014 | https://conductscience.org/library/papers/24514089 | PubMed |
| 22553438 | Influence of rifampin therapy on serum bactericidal activity in the presence of cloxacillin and vancomycin. | Can J Infect Dis | 1990 | https://conductscience.org/library/papers/22553438 | PubMed |
| 20065324 | Rifampin combination therapy for nonmycobacterial infections. | Clin Microbiol Rev | 2010 | https://conductscience.org/library/papers/20065324 | PubMed |
| 16495239 | In vitro activity of novel rifamycins against rifamycin-resistant Staphylococcus aureus. | Antimicrob Agents Chemother | 2006 | https://conductscience.org/library/papers/16495239 | PubMed |
| 11897604 | Combination of quinupristin-dalfopristin (Synercid) and rifampin is highly synergistic in experimental Staphylococcus aureus joint prosthesis infection. | Antimicrob Agents Chemother | 2002 | https://conductscience.org/library/papers/11897604 | PubMed |
| 8257135 | Influence of rifampin on fleroxacin pharmacokinetics. | Antimicrob Agents Chemother | 1993 | https://conductscience.org/library/papers/8257135 | PubMed |
| 7325636 | Characteristics of rifampin-resistant variants obtained from clinical isolates of Staphylococcus aureus. | Antimicrob Agents Chemother | 1981 | https://conductscience.org/library/papers/7325636 | PubMed |
| 7127231 | Rifampin therapy for Staphylococcus epidermidis endocarditis. | Can Med Assoc J | 1982 | https://conductscience.org/library/papers/7127231 | PubMed |
| 6859835 | In vitro activity of rifampin in combination with oxacillin against Staphylococcus aureus. | Antimicrob Agents Chemother | 1983 | https://conductscience.org/library/papers/6859835 | PubMed |
| 6732212 | Effect of rifampin and bacitracin on nasal carriers of Staphylococcus aureus. | Antimicrob Agents Chemother | 1984 | https://conductscience.org/library/papers/6732212 | PubMed |
| 3957435 | Efficacy of penicillin G, flucloxacillin, cefazolin, fusidic acid, vancomycin, rifampicin and fosfomycin in muscular infections in mice due to Staphylococcus aureus. | Infection | 1986 | https://conductscience.org/library/papers/3957435 | PubMed |
| 3707110 | Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus. | Antimicrob Agents Chemother | 1986 | https://conductscience.org/library/papers/3707110 | PubMed |
| 3031442 | Antimicrobial resistance of Staphylococcus aureus: genetic basis. | Microbiol Rev | 1987 | https://conductscience.org/library/papers/3031442 | PubMed |
| 2719468 | In vitro interaction between rifampin and clindamycin against pathogenic coagulase-negative staphylococci. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2719468 | PubMed |
| 2675760 | Methicillin-resistant staphylococci: detection methods and treatment of infections. | Antimicrob Agents Chemother | 1989 | https://conductscience.org/library/papers/2675760 | PubMed |
| 2128441 | Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. | Antimicrob Agents Chemother | 1990 | https://conductscience.org/library/papers/2128441 | PubMed |
| 2014980 | Rifampin resistance of Legionella pneumophila is not increased during therapy for experimental Legionnaires disease: study of rifampin resistance using a guinea pig model of Legionnaires disease. | Antimicrob Agents Chemother | 1991 | https://conductscience.org/library/papers/2014980 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/6901593
GET https://conductscience.org/api/papers/v1/6901593/cited_by?page=2